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Abstract

PROMOTION OF TUMOR CELL DEATH THROUGH THE INDUCTION OF
AUTOPHAGY IN HCT-116 COLON CANCER CELLS BY MICROTUBULE POISON,
JG-03-14

By Tuyen Nguyen, B.S. Biology
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2008

Major Director: Dr. David Gewirtz
Professor, Pharmacology and Toxicology

Microtubule poisons have proven to be effective in the treatment of a variety of
malignancies. Although taxol-based derivatives promote microtubule stabilization, there is
continuing interest in compounds that, like colchicines, act as microtubule destabilizing
agents. Previous work from this laboratory showed that the novel microtubule poison, JG03-14, was active against breast tumor cells, promoting autophagic cell death. In the
current work, we studied the influence of JG-03-14 on p53 wild type HCT116 colon
carcinoma cells. A crystal violet sensitivity assay indicated that JG-03-14 induced growth
8
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inhibition, with 75% suppression of growth evident at a concentration of 500 nM. Time
course studies of drug effects on cell viability indicated that JG-03-14 also produced cell
killing. FACS analysis demonstrated that the HCT-116 cells arrested in the G2/M stage;
furthermore, there was evidence of a hyperdiploid population that would be consistent with
failure of the cells to divide despite completion of DNA synthesis. Finally, there was
evidence of a small sub G0/G1cell population, indicating that the cells were not dying
primarily by apoptosis, and suggesting that JG-03-14 induces an alternative mode of cell
death. In contrast to cell shrinkage and nuclear fragmentation that was evident after
treatment with taxol ( a positive control for apoptosis), DAPI staining of HCT-116 cells
treated with JG-03-14 showed intact and enlarged nuclei, again consistent with the absence
of apoptosis. Furthermore, there was no evidence of mitotic catastrophe (micronuclei in
binucleated cells). Based on previous studies in MCF-7 and MDA-MB231 cell lines that
demonstrated a substantial population of autophagic cells, HCT-116 cells were subjected
to staining with acridine orange and monodansylcadaverine after treatment with JG-03-14.
While control cells tended to show a single large autophagic vesicle closely associated
with the cell nucleus, treatment with JG-03-14 resulted in extensive distribution of small
acidic vesicles within the cytoplasm, indicative of autophagy. GFP-LC3 transfected cells
incubated with JG-03-14 showed punctuated patterns that were also consistent with the
promotion of autophagy. Finally, activation of the DNA damage response pathway was
ruled out by the lack of induction of p53 and p21 in cells treated with JG-03-14. In
summary, our studies indicate that the JG-03-14 induces both growth arrest and autophagic
cell death in HCT116 colon carcinoma cells. The possibility of an alternative mode of cell

10
death induced by JG-03-14 makes it a potentially usefull candidate as a chemotherapeutic
drug that could be used to treat cancers resistant to apoptosis. Our result also suggested
that JG-03-14 failed to induce bone marrow toxicity adding to its potential for clinical use.
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CHAPTER 1 Introduction
I. Colon Cancer
In the US, cancer accounts for one in every four deaths, with colorectal
cancer as the second leading cause of cancer death (American Cancer Society,
2008). Death from colorectal cancer is attributed to the metastatic form of the
disease rather than the primary tumor (Delaunoit et al, 2005). Drug resistance
accounts for greater than 90% of treatment failure in patients with metastatic
disease, with colon cancer being completely refractory to currently approved
microtubule targeting agents, such as taxanes (Fojo et al, 2007; Sampath et al,
2006). The use of chemotherapy in the treatment of colon cancer would be
facilitated by the development of chemotherapeutic agents that have high potency,
efficacy in destroying the tumor cells, selectivity for the tumor target versus normal
host cells and refractory to the common resistance mechanisms in colon cancer.

II. Anti-tubulin compound for chemotherapy
Microtubules are crucial to cellular metabolism, intracellular transport, and
cell division (Nogales, 2001). A variety of natural compounds and their derivatives
have been shown to disrupt microtubule function (Xiao et al, 2005). These
compounds fall into two categories: microtubule stabilizers (polymerization) or
microtubule destabilizers (depolymerization); the latter group can be further
subdivided into those compounds that bind to the colchicine binding site of tubulin
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or the vinca alkaloid binding domain (Kuo et al, 2004). The microtubule stabilizers
such as paclitaxel (taxol), discodermolide, and epothilones stimulate the assembly
of purified tubulin whereas the destabilizers disrupt the assembly of purified
tubulin. Combretastatin A-4, podophyllotoxin and 2-methoxyestradiol (2ME2) are
microtubule destabilizers that bind to the colchicine binding site. Drugs that inhibit
microtubule dynamics can ultimately hinder normal mitotic spindle function,
leading to mitotic arrest and initiation of apoptosis or autophagy (Pasquier et al,
2008; Arthur et al, 2007).

III. Response to drug treatment
A. Apoptosis
Apoptosis is a form of programmed cell death that includes the extrinsic
pathway, which is activated by proapoptotic receptors at the cell surface and/or the
intrinsic pathway, which is activated by mitochondrial signals, where both
pathways converge on the executioner caspase, caspase 3, that signals to
effectors leading to cell death (Song et al, 2008; Wang et al, 2008; Ashkenazi and
Herbst 2008). In addition, apoptosis has also been shown to occur via a caspaseindependent mechanism (Cummings et al, 2004). Apoptosis is characterized by
membrane blebbing that pinches off into small apoptotic bodies, condensation and
fragmentation of the nucleus and DNA (Taylor et al, 2008). Activation of apoptosis
can occur via the DNA damage response protein p53 or by a p53 independent
mechanism (Gulbins et al, 2000). Resistance to chemotherapy that is associated
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with the p53 dependent induction of apoptosis is often related to mutations in p53
and evasion of the p53 signaling pathway (Chendil et al, 2000).
B. Autophagy
Autophagy is characterized by the sequestration of proteins and organelles
into a double membrane acidic vesicle that eventually becomes degraded (Figure
C) (Gozuacik and Kimchi, 2004). The process begins with a double membrane
that enwraps around a portion of the cytosol, containing organelles and proteins,
to form the autophagosomes. The autophagosome then fuses with the lysosome,
forming an autolysosome, where the contents are degraded. This process is
conserved from yeast to human but differs in the site of induction, with preautophagosomal structures (PAS) next to the vacuole in yeast but with multiple
sites in mammalian cells (Jahreiss et al. 2008; Qadir et al, 2007). There are three
types of autophagy, microautophagy, macroautophagy, and chaperone-mediated
autophagy, but these will not be distinguished for the purpose of this study. It has
been shown that autophagy can be activated by the PI3K-Akt-mTor pathway,
nutrient deprivation, ceramide, and Atg proteins (Lavieu et al, 2007; Mizushima et
al, 2008). Chemotherapeutics drugs have also been shown to promote autophagy
in tumor cells (Cui et al, 2007).
The process of autophagy under nutrient deprivation is under the control of
the PI3-K-Akt-mTor pathway (Ravikumar et al, 2004). When nutrients are
abundant, the mTor pathway is activated and inhibits autophagy; however, under
conditions of nutrient depletion, mTor becomes inactivated and autophagy is no
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longer suppressed. Though the process of autophagy by nutrient deprivation is
well characterized, the role of autophagy in response to chemotherapeutic drugs
requires extensive investigation.
A widely used method for detection of autophagy is to monitor the levels of
autophagy associated proteins . The yeast Atg8 homologue MAP-light chain
3(LC3) appears to have a crucial role in the expansion and completion of
autophagosome formation (Kouno 2005; Kabeya et al. 2000). MAP-LC3 is
cleaved by a cysteine protease Atg4 and activated by Atg7 to produce LC3-I,
found in the cytosol (Sou et al. 2006). After its generation, LC3-I is converted to
LC3-II via the actions of E1 and E2 (both are ubiquitin like proteins, Atg7 and Atg3
respectively) and locates to the autophagic membrane. The target of LC3-II has
been identified to be phosphatidylethanolamine (PE), found on the
autophagosome membrane. This tight binding between LC3-II and PE is thought
to promote autophagosome maturation and then fusion of the autophagosome
with the lysosome to complete autophagy (Asanuma et al, 2003; Sou et al, 2006;
Tanida et al, 2002).
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Figure C – Autophagy pathway

IV. Drug Resistance
The clinical success of cancer chemotherapy is often limited by the
challenge of resistance to antitumor drugs by cancer cells. Some relatively
frequent mechanism of resistance includes decreased drug accumulation in tumor
cells, drug inactivation in tumor cells, increased DNA repair, and amplification or
mutation of drug target genes (Eastman and Schulte, 1988; Lai et al, 1988; Cazin
et al, 1992). Some of the enzymes responsible for drug inactivation includes
glutathione S-transferase and aldehyde dehydrogenase (Hoban et al, 1992; Hilton,
1984) Drug resistance pumps are often responsible for the decrease in drug
accumulation in cancer cells and can involve p-glycoprotein, a membrane pump
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that can extrude a wide range of antitumor drugs, as well as other multidrug
resistant protein pumps (Harris et al, 1992; Baines et al, 1992; Lizano et al, 1993
.) Chemotherapeutic drug resistance is a cause of frequent treatment failure in
colon cancer (Fojo et al, 1987; Hengstler et al, 1998). Resistance to drugs that
are widely used in the treatment of colon cancer such as the antimetabolite 5fluorouracil, the topoisomerase I inhibitor irinotecan, and the DNA damaging
agent, oxaliplatin, have been reported (Boyer et al, 2004; Oliver et al, 2002). Loss
of response to apoptosis mediated cell death can often be attributed to a defect in
p53 status (Violette et al, 2002). As a result, drug development requires the
identification of compounds that are poor substrates for the multidrug efflux
pumps. In addition, drug combination treatments represent a strategy to evade
the intrinsic drug resistance mechanisms of tumor cells (Hiro et al, 2008).

V. Substituted pyrroles as anti-tumor drugs
Pyrroles are components of a more complex macrocycle that is made up of
a substituted aromatic ring structure Figure A. They are components of the
complex macrocycles such as porphyrin of heme and the chlorines and
bacteriochlorins of chlorophyll (Katsiaouni et al, 2008; Wu et al, 1985). Pyrrole
compounds such as CC-1065, distamycin and duocarmycins are a natural class of
antibiotics that have antitumor activities (Shinohara et al, 2006; Nagamura et al,
1996; Hiraku et al, 2002). Prompted by the readily available natural material and
the ability to make major or minor alterations to the natural structure has led
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researchers to screen for more natural products. Lamellarins are another class of
pyrroles that have been obtained from a natural source, the marine prosobranch
mollusk, and which have been shown to have antitumor activity as well as the
capacity to reverse multidrug resistance (Quesada et al, 1996; Davis et al, 1999).
It was observed that lamellarins along with many marine derived pyrroles possess
a 3,4-diarylated pyrrole 2-carboxylic acid ester or amide moiety (Fan et al, 2007).
The oxygenated 3,4-diaryl substitution appears to be associated with the MDR
reversal behavior while the phenolic hydroxyl groups are associated with the
cytotoxic behavior (Gupton 2006).

Figure A – Structure of a pyrrole

The discovery of drug templates derived from natural sources, where
modifications to maximize pharmacokinetics and pharmacodynamic properties of
the compound are easily performed, has led to the generation of versatile
synthetic analogs.
A recent class of substituted pyrrole compounds is based on a 3,4diarylated pyrrole 2-carboxylic acid ester Figure B. Out of the group of
brominated pyrroles, JG-03-14 has been shown to bind at the colchicine binding
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site of tubulin between the alpha and beta interfaces on purified tubulin (Mooberry
et al, 2007). Studies have indicated that JG-03-14 is cytotoxic at a concentration
of 500nM and it has been demonstrated to initiate both apoptosis and autophagy
in MCF-7 and MDA-MB-231 breast tumor cells (Arthur et al, 2007). While some
studies in the literature suggest that functional p53 is required for autophagy
(Abida and Gu, 2008) JG-03-14 also induced autophagy in p53 mutant MDA-MB231 breast cancer cells. The mechanisms by which JG-03-14 induces autophagy
in MCF-7 and MDA-MB-231 breast cancer cells and the role of functional p53
requires further elucidation.
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Figure B- Strucutres of the substituted pyrroles. JG-03-14 is used in this
study.

The aim of our study was to determine if JG-03-14 might also have antiproliferative
and or cytotoxic effects in HCT116 colon carcinoma cells, the mode(s) of cell
death is induced by JG-03-14, and whether the compound activates p53 proteins
and/or p21Waf1/Cip1.
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CHAPTER 2 Materials and Methods
Cell Culture
HCT116 p53 wild type colon carcinoma cells were obtained from ATCC and
kept frozen in 10% DMSO (Sigma Chemical, St. Louis, MO) with Fetal Bovine
Serum (FBS)(GIBCO Life Technologies, Gaithersburg, MD) until use. Cells were
quickly thawed and cultured in a T75 flask (Cellstar) in basal RPMI 1640 medium
supplemented with 5% fetal bovine serum, 5% bovine calf serum, 2 mM Lglutamine, and penicillin/streptomycin 0.5 ml/100 ml medium(10,000units/ml
penicillin and 10 mg/ml streptomycin; GIBCO Life Technologies, Gaithersburg,
MD) at 370 C under a humidified, 5% CO2 atmosphere. Cells were passaged at
80% confluency by washing one time with 1X PBS(GIBCO), harvested with
trypsin-EDTA 0.25 %(GIBCO) and then deactivated with RPMI medium, collected
and centrifuged at 15,000 rpm for 3 minutes. Media was aspirated and fresh
media was added to the cell pellet; cells were re-suspended in media and 300 µl of
the cell resuspension was placed into a fresh T75 flask with 10mL RPMI medium.
For all culture experiments, cells were plated and permitted to adhere overnight
before drug treatment. All treatment involved continuous drug exposure.
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MTT assay
Cells were prepared as described above. Using a 96 well plate, 5,000
cells/150uL media were plated per well and allowed to adhere overnight before
drug treatment. After 72 hours, 100 µl of the MTT solution ( 2mg/mL PBS
prepared in the dark) was added to each well and incubated for 3 hours at 370 C
The MTT solution was removed and 100µl of DMSO was added to each well, and
the blue dye was allowed to dissolve for 5 minutes. An absorbance reading was
taken at 490 nm (KC Junior software, EL800 Universal Microplate Reader).

Crystal Violet Assay
Cells were prepared as described above. The crystal violet assay, as
described by Wosikowski et al, (1993), was used to determine drug effects on cell
viability. In a 48 well plate, 20,000 cells /500 µl media were plated per well and
allowed to adhere overnight. After 72 hours of treatment, the drug was aspirated
and the cell monolayer was fixed with 100% methanol for 10 minutes. The
methanol was aspirated and a crystal violet 0.5% solution in 25% methanol was
used to stain the cells for 10 minutes. The stain was removed and cells were
washed 4 times to remove excess dye. Fixed cells were left to air dry overnight.
The next day, cells were solubilized in 1 ml 0.1 M sodium citrate in 50% ethanol
and placed on a shaker for 10 minutes. Absorbance readings were taken at
540nm.
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Time Course of Drug Effects on Viable Cell Number
Cells were prepared as described above. Cells were plated at 1X10^6 cells per 96
mm Petri plate (CellStar) and allowed to adhere overnight. At the various time
points, media containing the drug was aspirated and cells were washed once
using 1X PBS. Cells were then harvested and centrifuged at 15,000 rpm for 3
minutes and media was removed. The cell pellet was resuspended in fresh media
and 10µl of the cell resuspension was added to 90µl of 0.4% trypan blue
exclusion dye (1:9; trypan blue: PBS). 10µl of the mixture was placed onto a
hemocytometer and viable cells (those that excluded the dye) were counted using
the phase contrast microscopy.

DAPI Staining for Apoptosis and Mitotic Catastrophe
Cells were prepared and treated as in the time course studies, above. The
assay used was from Gavrieli et al, 1992. At the various time points, adherent and
non-adherent cells were harvested and centrifuged at 15,000 rpm for 3 minutes.
The media was aspirated and fresh media was added to resuspend the pellet.
Viable cell numbers was determined using trypan blue exclusion dye as described
previously. A dilution of 20,000 cells in 200 µl of 1X PBS per slide was prepared
and cells were spun at 10,000 rpm for 5 minutes (Shandon Cytospin 4, Thermal
Electron Corp). Slides were refrigerated until ready for staining. Cells were fixed
with 4% formaldehyde in PBS for 10 minutes at room temperature, and then
washed with PBS twice for 5 minutes at room temperature. A 1:2 dilution of acetic
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acid and ethanol was used to fix the cells at 200 C for 5 minutes. The slides were
then washed twice with PBS for 5 minutes at room temperature. A 1:1000 dilution
was prepared for Vectashield :Dapi and each slide was mounted with 10µl of the
solution. Coverslips were sealed using clear nail polish and photographs were
taken at 10X using a Nikon fluorescent microscope and an Olympus camera.
Slides were stored at 4 0 C , and three field per condition were evaluated.

Flow Cytometry
Cells were plated at 3 million cells per 96 mm Petri plates for each time
point and allowed to adhere overnight. Setup was prepared for day 5 and worked
backward so that all treatments would complete on the same date. Drug treatment
was initiated the following day and drug was left on the cells for continuous
exposure. Upon the completion of treatment, media was aspirated and cells were
washed one time with 1X PBS. Cells were harvested using trypsin and
deactivated with 10ml media, then centrifuged at 15,000 rpm for 3 minutes. Media
was aspirated and the cell pellet was resuspended in fresh media. Viable cell
number was determined by trypan blue exclusion dye. At least 1 million cells per
condition were used in the cell cycle analysis. 1.5 ml of Propidium iodide stain
with RNAse was added to each million cells. The cell suspension was filtered
through a 70 micron mesh 2 times. All samples were covered in aluminum foil and
refrigerated until the next day. FACs acquisition was performed using the EPICS
753 flow cytometer (Coulter Electronics, Hialeah, FL) using a 488 nm argon laser
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and standard optical emission filters. A minimum of 13,000 events were collected
per sample. Cellular DNA distributions were analyzed at the various stages of the
cell cycle using Cytologic Software (Coulter Electronics).

Acridine Orange staining for autophagy
As a marker for autophagy, the acridine orange staining method described
by Paglin et al, (2001) was used. Cells were plated at 2 X 10^5 per 6 well plate
and allowed to adhere overnight. Drug was added the following day and left on for
continuous exposure. At the final time point, the drug was removed and cells were
washed one time with 1X PBS. Cells were then stained with acridine orange
(1ug/ml) for 15 minutes. .

Monodansylcadaverine
Monodansylcadaverine(MDC) is another marker for autophagy that stains
the autophagic membrane (Niemann et al, 2000). Cells were treated as described
above. MDC(Sigma) was dissolved in DMSO for a stock concentration of 100
mM. At selected time points, cells were stained with 0.5 mM
monodansylcadaverine for 10 minutes. The stain was removed and cells were
washed with 1X PBS four times before fresh media was added to the wells.
Pictures were taken with the inverted Nikon fluorescent microscope and an
Olympus camera at 20X magnification
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Transfection with GFP-LC3
As a marker for autophagy, LC3 tagged GFP was used to detect the
processing of the LC3 proteins in the autophagosomes (Kabeya et al, 2000). Cells
were prepared from frozen stock and passaged twice at least 2 days before
nucleofection. 1 X 10^6 cells were centrifuged and suspended in a pellet. 100 µl
of the Nucleofector V (Nucleofector Kit V, Amaxa) mix was added to resuspend
the cells. The resuspension was added to 1 µg of the GFP-LC3 vector and the
entire suspension was transferred to the cuvette. The cuvette was placed in the
Nucleofector device and program D-032 was used to transfect the cells. 500 µl
warm medium was added to the transfected solution and the total suspension was
transferred to a Petri plate. These steps were repeated for the positive and
negative controls using 2 µg of empty vector-GFP, and 2 µg pmax-GFP.

Western Blotting
After the indicated times, cellular proteins were extracted from treated cells
using 100 to 200 µL of 1X tris lysis buffer (1 M Tris(pH 6.8), 10% SDS, and dH2O)
containing protease inhibitors with boiling for 5 minutes. Protein concentration
was determined with a Lowry protein assay and 10 µg of total cell lysates were
separated using 12% SDS-PAGE. Proteins were transferred onto nitrocellulose
membrane for 1 hour and blocked in TBS-Tween 20 buffer containing 5% nonfat
dry milk. Membranes were then immunoblotted with the respective primary
antibodies overnight in 200 C. The following day, the membrane was incubated
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with horseradish peroxidase-conjugated secondary antibody for 1 hour. Signals
were detected using an enhanced chemilluminescence detection reagents from
Pierce (Rockford, IL).

Assessing Bone Marrow Toxicity
Two C57BL6 mice were sacrificed by cervical-cranial dislocation. The
femur and tibia of both mice were removed and all exo-skeletal parts were
removed. All muscle tissue was scraped off with a scalpel and bones were placed
in 1X PBS. The femur was cut at both ends to expose the hollow bone and fresh
1X PBS was used to wash out the bone marrow cells using a 23 G needle. The
same process was repeated for the other femur and tibias after which the cell
suspension was spun down at 10,000 rpm for 3 minutes. The pellet was washed
with 1X PBS and re-centrifuged. To lyse red blood cells, red cell lysis buffer was
added to the pellet and incubated at 370 C for 5 mins. Cells were centrifuged and
washed with 1X PBS. The bone marrow cell pellet was resuspended in 1 ml RPMI
medium supplemented with 30% serum. Cells were counted and plated at 2X10^5
cells/0.5ml medium. Drug was added directly to the cell suspension with
incubation for 72 hours. Cell viability was evaluated using Alamar Blue dye (10%
dissolved medium) and absorbance of 570 nm and 600 nm was taken after 30
minutes with the KC Junior microplate reader.
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Statistical Analysis
Statistical analysis was performed using a two-tailed student’s T test;
groups with p ≤ 0.05 were considered to be significantly different than vehicle
controls.
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CHAPTER 3 Results
I. Effects of JG-03-14 on the DNA damage response pathway in MCF-7
breast tumor cells.
In previous studies, (Mooberry et al., 2007) the novel substituted pyrrole
compound, JG-03-14, was shown to inhibit the polymerization of purified tubulin in
vitro; evidence was also presented that JG-03-14 bound to the colchicine binding
site on tubulin. In a separate report utilizing molecular modeling, it was
determined that JG-03-14 was likely to form a very stable complex with high
affinity to tubulin, suggesting a promising role for this compound as a
chemotherapeutic agent (Tripathi et al, 2008). Studies within our laboratory
demonstrated that JG-03-14 promoted cell death in both p53 wild-type MCF-7 and
p53 mutant MDA-MB-231 breast tumor cells; furthermore, JG-03-14 retained
activity in multi-drug resistant cells (Arthur et al., 2007; Mooberry et al, 2007).
Although both of the studies cited above supported the concept that JG-0314 acts as a microtubule poison, it was important to test and eliminate the
possibility that JG-03-14 might also act through the induction of DNA damage.
Since DNA damaging agents generally induce p53 and p21 (Lanni and Jacks,
1998), Western blotting was performed using antibodies against p53 and p21 after
exposure of MCF-7 cells to JG-03-14. Figure 1 shows that 10 Gy of irradiation (a
positive control) induced p53 at 1h and 2h and p21 at 2h and 4h. JG-03-14 failed
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to induce p53 or p21, indicating that there was no DNA damage response to JG03-14 in the p53 wild type MCF-7 cells.

II. Effects of JG-03-14 and other microtubule poisons on viability of
HCT-116 colon cancer cells
Due to JG-03-14’s ability to cause cytotoxicity in cells expressing the multidrug resistant phenotype, we chose to analyze its potential to interfere with growth
and or cause cell death in colon tumor cells as these cancers are notorious for
acquiring resistance against drugs such as colchicine, vinblastine, lapatinib and
mitomycin (Incles et al., 2003; Martin et al., 2008). We selected p53 wild type
HCT-116 cells because of the availability of isogenic derivative cells lines where
p53 or p21 function have been silenced (for future work).
Sensitivity of HCT-116 colon tumor cells to JG-03-14 was determined using
the Crystal Violet Assay (Wosikowski et al. 1993). Cells were treated with the
compound by continuous exposure for 72 hours prior to fixation and staining.
Figure 2A indicates that JG-03-14 demonstrated concentration-dependent growth
inhibition; at concentrations of 250 nM and 500nM, substantial growth inhibition
was observed compared to the untreated controls. Treatment with adriamycin at
100nM was used as a positive control. All subsequent studies were performed
using JG-03-14 at a concentration of 500 nM.
For comparative purposes, we also assessed sensitivity of HCT-116 cells to
two other microtubule poisons, colchicine and taxol. Colchicine causes
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microtubule disruption, like JG-03-14, while taxol is a microtubule stabilizer.
Figure 2B shows that after 72 hours of continuous drug treatments, the three
compounds all reduced viable cell number by approximately equivalent amounts,
with a reduction of 75% by JG-03-14, 82.5% by colchicine and 67% by taxol.

III. Cell death of HCT-116 cells after exposure to JG-03-14 and other
microtubule poisons
The crystal violet studies do not distinguish between the effects of drugs on
cell growth arrest or viability. Consequently, we monitored the effects of JG-03-14
on cell viability over a period of 5 days. Figure 3A shows a time dependent
decline in viable cell number when HCT116 cells were treated by continuous
exposure to JG-03-14 at 500nM, a concentration that we have previously found to
be effective in promoting breast tumor growth arrest and cell death (Arthur, 2007).
All the microtubule poisons produced a similar time-dependent decline in viable
cell number (Figure 3B).

IV. Assessment of apoptosis in HCT-116 cells after treatment with JG03-14 and other microtubule poisons
The possibility that the cell death observed in HCT-116 in a time dependent
manner might be due to apoptotic events was assessed using 4’,6-diamino-2phenylindole (DAPI), a blue fluorescent nucleic acid stain that binds to double
stranded DNA. Figure 4 shows the untreated vehicle control with a clearly
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defined intact nucleus; in contrast, our positive control, treatment with 10 µM taxol,
shows nuclear fragmentation characteristic of apoptosis. The nuclei of cells
treated with JG-03-14 treated were intact, similar to the untreated cell and vehicle
controls; however, nuclei of cells treated with JG-03-14 were significantly
enlarged.
Since the positive taxol 10 µM control was not a pharmacologically relevant
concentration, we also assessed the effects of colchicine (100nM) and taxol
(100nM) on nuclear integrity. Dapi staining showed that the majority of nuclei
were fragmented by both treatments after three days (Figure 4).

V. Cell cycle effects of JG-03-14 and other microtubule poisons on
HCT-116 tumor cells
Microtubule poisons generally produce G2/M arrest in tumor cells (Tseng et
al, 2002). JG-03-14 also produced a G2 arrest in the p53 wild type MCF-7 cells
(Arthur et al, 2007). The next series of experiments were designed to evaluate the
nature of growth arrest by JG-03-14 as well as to verify the absence of apoptosis.
Figure 5 presents FACS analysis of cells treated with JG-03-14 at various time
points. JG-03-14 transiently arrested the p53 wild type HCT-116 tumor cells in the
G2/M cell phase after the first day of treatment, consistent with its microtubule
destabilizing abilities. This G2/M block persisted for 72 hours. Of particular
interest was the ability of p53 wild type HCT-116 cells to continue to replicate
following the G2/M arrest, resulting in a hyperdiploid population. This effect was
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observed after the first day of treatment and the hyperdiploid cell population had
more than doubled after 72 hours, where 21 % of the cells were polyploid. FACS
analysis confirmed the absence of cells in a sub G1 population both at 24 and 72
hours following the incubation with 500 nM JG-03-14, confirming the absence of
apoptosis in HCT-116 p53 wild type cells.
We also evaluated the effects of the microtubule destabilizer, colchicine, on
cell cycle distribution. At a concentration of 100nM, where cell growth is inhibited
by 90% (Figure 3), approximately half the population arrested in the G1 phase
and the other half accumulated in G2/M after 24 hours (Figure 5). This was
shifted to a 49% G2/M arrest and 4.5% in G1 after 72 hours. A similar cell cycle
distribution was observed in cells treated with JG-03-14 after 72 hours, where 63%
were arrested in G2/M and 4.5% were in G1. Colchicine also induced polyploidy
in the HCT-116 cells. 2% of the population were hyperdiploid after 24 hours and
14.7% was hyperdiploid after 72 hours, coinciding with the characteristic of
microtubule destabilizers (Morrison and Rieder, 2004). Approximately 34% of the
cell population consisted of sub G1 cells after 24 h, indicating that approximately
one-third of the cells were undergoing apoptosis, a characteristic consistent with
colchicine treatments in other studies (Bonfoco et al, 1995; Wang et al, 1999).
This finding is also consistent with the DAPI staining studies shown in Figure 4.
In contrast to the effects of the microtubule destabilizing agents, colchicine
and JG-03-14, the microtubule stabilizing agent, taxol, at 100nM, arrested the cells
primarily in the G1/S phase. Approximately 42% and 60% of the cells were in G1

33
after 24 and 72 hours, respectively. A significant fraction of the cell population (20
%) was in the sub G1 phase after 24 hours, with an increase to 30% after 72
hours. Again, the capacity of taxol to generate a sub G1 cell population confirmed
the presence of apoptosis in HCT-116 cells that was indicated by the DAPI
studies.

VI. Assesment of mitotic catastrophe in HCT-116 cells after JG-03-14
treatment
We concluded that our p53 wild type HCT-116 cells were not succumbing to
death via apoptosis after treatment with JG-03-14, based on our Dapi staining and
FACS analysis. Due to the presence of enlarged cells and a hyperdiploid cell
population we considered the possibility of mitotic catastrophe being the mode of
cell death in HCT-116 tumor cells. However, Figure 4 failed to demonstrate binucleated cells and micronuclei that are characteristics of mitotic death
(DeMasters et al, 2006).

VII. Induction of autophagy by JG-03-14 in colon cancer cells.
In our previous work, the p53 wild type MCF-7 and p53 mutant MDA-MB231 breast tumor cells demonstrated essentially similar sensitivity to JG-03-14;
however, their response was different with regard to the modes of cell death.
MCF-7 cells were not dying through apoptosis based on the FACS analysis and
TUNEL assay, but rather through autophagy. MDA-MB231 cells demonstrated
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both apoptosis and autophagy. Since the MDA-MB231 cells are p53 mutant
cancer cells, both apoptotic death and autophagy can be independent of the p53
pathway.
Our studies suggested that the death of the p53 wild type HCT-116 colon
cancer cells was not triggered through apoptosis after treatment with JG-03-14
based on the DAPI staining and FACS analysis. The lack of micronuclei and
binucleated cells in Figure 4 also ruled out the possibility of mitotic death. Since
JG-03-14 was shown in our previous work to promote autophagy in both MCF-7
and MDA-MB231 breast tumor cells, we also assessed this possibility in the HCT116 colon carcinoma cells using acridine orange staining. Figure 6 shows that the
untreated control had a uni-vesicular stain that was situated near the nucleus. In
dramatic contrast, the cells treated with JG-03-14 exhibited a more punctuate
staining that was distributed throughout the cytoplasm. The cells treated with JG03-14 were also quite enlarged, nearly double the size of the untreated cells, likely
due to the increased DNA content.
We also evaluated the capacity of the microtubule poisons, colchicine and
taxol, to promote autophagy, Figure 7. Surprisingly, a similar pattern of
punctuated stained vacuoles were also exhibited in cells treated with colchicine
and taxol, both at 100 nM concentrations. This was not expected due to the large
apoptotic population observed by FACS analysis and the fragmented nuclei
evident with DAPI staining.
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VIII. Confirmation of the induction of autophagy by JG-03-14
To confirm the promotion of autophagy, we used an additional approach,
staining of autophagic vesicles with monodansylcadaverine. This is a selective
stain that binds to the lipid membrane of the autophagosomes, and which would
be more sensitive to the presence of autophagosomes, unlike the acridine orange,
which primarily detects the acidic pH of the autophagic vacuoles (Niemann et al.,
2000; Biederbick et al., 1995). Figure 8 compares the cells treated with JG-03-14
and controls. After day 3, a substantial amount of monodansylcadaverine staining
of the autophagic vacuoles is evident in the treated cells compared to the control,
which showed a single stain that was centered on a uni vacuole, similar to what
was present in the acridine orange stains. The monodansylcadaverine positive
stained vacuoles also showed a highly distributed punctuate pattern throughout
the cytoplasm. The staining with both acridine orange and monodansylcadaverine
confirmed the presence of autophagosomes in HCT-116 cells treated with 500 nM
JG-03-14. The presence of autophagosomes was also detected in cells incubated
with either 100 nM taxol or colchicine (Figure 7 and 8).

IX. Assessment of LC3-II protein levels in HCT-116 cells tested with
JG-03-14
In efforts to further confirm that autophagy may be the mechanism by which
JG-03-14 is inducing cell death, we performed western blotting to detect
conversion of LC3-I to LC3-II at various time points. LC3-I conversion to LC3-II is
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required for autophagosome maturation and is found both inside and outside the
vesicle (Amer et al, 2005). We attempted multiple times using both other tumor cell
lines and cells transfected with GFP-LC3-II via lipofection and nucleofection but
failed to obtain a clear and reproducible western blot with LC3-II. Our blots
showed stains that were just background noise, irrelevant to our interest. We tried
using three different antibodies from three different companies that also failed to
produce anything close to clean blots (data not included).

X. Detection of LC3-II punctate in HCT-116 cells with JG-03-14
treatments
LC3-II is a cleaved product of LC3-I and is involved in the formation of
autophagosomes (Kabeya et al, 2000). We attempted to confirm that autophagy
was occurring by detecting the presence of LC-3 II in the treated cells. HCT-116
colon tumor cells were transfected with a GFP-LC3 vector via nucleofection and
the cells were observed under immunofluorescence after 72 hours with 500 nM
JG-03-14. After 72 hours of drug treatment, the transfected cells showed a
punctuate distribution of LC-3 II proteins in the cytoplasm (Figure 9) whereas cells
transfected with the empty vector lacked any punctuated stains. Due to the low
efficiency of transfection and the relatively short life of the GFP fluorescent dye,
there were very few cells remaining which exhibited the fluorescence after 72
hours.
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XI. Effects of autophagic inhibitors on the response to JG-03-14
treatment in HCT-116 cells
There is continuing controversy in the literature as to whether autophagy is
a cytoprotective mechanism or an actual mode of cell death(Mori et al, 2007; Boya
et al, 2005). In a further attempt to confirm the mode of cell death caused by JG03-14 and to elucidate the ambiguous role of autophagy, we sought to block
autophagy. In efforts to address this question, cells were treated with 3methyladenine (3-MA), which has been shown to inhibit autophagy (Seglen and
Gordon, 1982). HCT-116 cells were incubated with both 25mM 3-MA and 500 nM
JG-03-14, after which cells were stained with acridine orange at the various time
points. Our untreated controls exhibited one acidic vesicle situated near the
nucleus as shown in Figure 10. Cells exposed to JG-03-14 showed distributed
acidic vesicles that were throughout the cytoplasm. 3-MA however, did not inhibit
or decrease the generation of acidic vesicles by JG-03-14. Cells were still
enlarged and highly punctuated with autophagosomes (Figure 10). There was no
noticeable difference evident between cells treated with JG-03-14 alone and those
that were co-treated with 3-MA, suggesting that it was necessary to identify an
alternative means to interfere with autophagy.
Bafilomycin A-1 is a macrolide antibiotic that was shown to inhibit
autophagy at high concentrations (Shacka et al., 2006). Using the MTT assay,
contradictory results were obtained in terms of the cytotoxicity of bafilomycinA1(data not shown). Due to the conflicting results of the experiments using the
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MTT assay, we reverted to using the crystal violet assay to test for sensitivity.
Using this assay, Bafilomycin-A1 at 100 nM did not show any growth inhibition.
When cells were treated with Bafilomycin-A1 in combination with JG-03-14 at 500
nM, there was no reduction in the cytotoxic effects of JG-03-14 (Figure 11A). We
then went on to test the inhibitory effect of Bafilomycin-A1 on autophagy. Cells
were co-incubated with JG-03-14 (500nM) and Bafilomycin-A1 (100 nM) with
continuous exposure prior to acridine orange staining. Figure 11B showed that
there was no difference in the extent of autophagy with JG-03-14 alone and with
JG-03-14 combined with the autophagy inhibitor, Bafilomycin-A1 (Figure 8).

XII. Effects of JG-03-14 on the DNA damage stress response activation
pathway in HCT-116 cells
Although we appear to have ruled out activation of the DNA damage
response pathway by JG-03-14 in the MCF-7 cell studies (Figure 1) it remained
possible that JG-03-14 might be activating this pathway in the HCT-116 cells. To
examine this possibility western blotting was performed at 4 and 8 hours to detect
levels of p53 and p21. Figure 12 indicates that JG-03-14 alone did not induce p53
at 4 and 8 hours similar to the untreated controls. However, the treatment with
taxol or colchicine showed induction of p53 or p21 at 4 and 8 hours. Irradiation at
10 Gy was also used as a positive control.
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XIII. Evaluation of the impact of JG-03-14 on bone marrow toxicity
Bone marrow toxicity is a major concern with cancer chemotherapy. In
order for JG-03-14 to be clinically successful, it should not express this mode of
toxicity. Figure 13 showed the effects of JG-03-14 on hematopoietic cell viability
using Alamar Blue staining. JG-03-14 showed no suppression of bone marrow
cell growth while taxol and adriamycin produced small effects.
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Figure 1- Lack of induction of p53 and p21 by JG-03-14 in MCF-7 breast tumor cells.
MCF-7 cells were incubated with JG-03-14 (500nM) for the time periods indicated before
harvesting and subjecting cell lysates to western blotting. Irradiation (10 Gy) was used as
a positive control and beta actin was the loading control. p53 and p21 were induced by
irradiation (lanes 4, 7, and 9).
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Figure 2 – Drug sensitivity of HCT-116 colon carcinoma cells by the Crystal Violet
assay. A. Sensitivity to JG-03-14. B. Sensitivity to other microtubule poisons. Cells were
seeded in a 48-well plates and incubated with the indicated compounds at the various
concentration for 72 h. DMSO was a negative control and Adriamycin was used as a
positive control. Values shown represent means ± standard errors for three replicate
experiments. Growth inhibition at 250 nM and 500 nM JG-03-14 was statistically
significant compared to vehicle controls with p ≤ 0.05 for HCT-116 cells.
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Figure 3 – Growth arrest and cell death in HCT-116 cells. Cell death was evaluated in
response to a continuous 5 day exposure to 500 nM JG-03-14, 100nM colchicine or 100nM
taxol. Cell viability was monitored using trypan blue exclusion. Studies were independent
of each other. A. Time course response of HCT-116 cells to JG-03-14. Adriamycin (100
nM )was used as our positive control (not shown). B. Time course response of HCT-116
cells to JG-03-14 500nM, colchicines 100nM and taxol 100nM. Values shown represent
means ± standard errors for three replicate experiments.
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Figure 4– Assessment of effects of JG-03-14 on nuclear integrity of HCT-116 cells.
HCT-116 cells were treated with the various drugs by continuous exposure. After 72 h,
slides were prepared with adherent and non-adherent cells, fixed, and stained. Cells treated
with JG-03-14 showed very minimal nuclear perturbations compared to the pronounced
nuclear fragmentation evident in treatments with taxol and colchicine.
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Figure 5- Influence of JG-03-14 on cell cycle progression of HCT-116 cells. Cell cycle
distribution was determined by flow cytometry of HCT-116 cells exposed to the various
microtubule compounds. Cells were exposed for 72 h, at which time were harvested and
stained with propidium iodide staining (PIF) solution. Flow cytometry PIF voltages were
altered for the treatment groups compared to the control to accommodate the increasing
polyploidy observed following drug treatment at 24h and 72 h.

46
Control

JG-03-14

47
Figure 6- Determination of autophagy by acridine orange staining. HCT-116 cells were
incubated with JG-03-14 at 500 nM for 3 days, stained, washed, and observed by
fluorescence microscopy. Green stain reflects the background while bright orange staining
occurs in acidic (autophagic) vacuoles. Although the control showed one acidic vacuole ,
it was localized to the nucleus and is different from the accumulation of the distributed
autophagic vacuoles seen in treatment with JG-03-14. All photos are taken at 20X.
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Figure 7 - Comparing autophagy by microtubule poisons in HCT-116 cells using acridine
orange staining. HCT-116 cells were incubated with the different treatments for 3 days,
stained, washed, and observed by fluorescence microscopy. These photos were taken
without the green background which better differentiates the staining. Bright orange
staining occurs in acidic (autophagic) vacuoles. Although the control showed one acidic
stained vacuole, it was localized to the nucleus and is different from the accumulation of
the distributed autophagic vacuoles seen in our treatment with JG-03-14. All photos were
taken at 20X.

49
Control

Thapsigargin

Colchicine 100 nM

Bafilomycin 100 nM

Taxol 100 nM

JG-03-14 500 nM

JG-03-14 500 nM + Bafilomycin 100 nM

Figure 8– Determination of autophagic vacuole formation using monodansylcadaverine
(MDC) staining. HCT-116 cells were incubated with the different microtubule poisons for
3 days, stained, washed, and observed by flurescence microscopy. Bright blue staining
occurs in the autophagic membrane Thapsigargin 0.5 uM was used as our positive control.
All photos were taken at 20X.
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Figure 9– Detection of the LC3-II protein in cells treated with JG-03-14. HCT-116 cells
were transfected with (A) GFP (B) empty-GFP vector (C) GFP-LC3-II vector and treated
the following day with JG-03-14 (500 nM, continuous exposure for 72 h). Photos were
taken at 10 X for (A)-(C) and 40X for (D).
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Figure 10–Effects of the autophagy inhibitor, 3-methyladenine (3-MA) on the response of
HCT-116 cells to JG-03-14. HCT-116 cells were co-incubated with JG-03-14 (500 nM)
and 3-MA (25 mM) by continuous exposure for 3 and 5 days, stained with acridine orange,
washed, and observed by fluorescence microscopy. Acidic stained vacuoles were still
present even after day 5. All photos were taken at 20X
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Figure 11- (A) Growth inhibition with the combination treatment was assessed using the
crystal violet assay. Cells were seeded in a 48-well plates at 20,000 cells per well and
incubated with the indicated compounds for 72h. The combination of JG-03-14 500 nM
and Bafilomycin-A1 100 nM was added for continuous exposure. DMSO was our
negative control. Values shown represent means ± standard errors for three replicate
experiments. (B) Treatment of HCT-116 cells using the autophagy inhibitor,
Bafilomycin-A1. HCT-116 cells were plated in a 6-well plate and co-incubated with JG03-14 (500 nM) and Bafilomycin-A1 (100 nM) continuous exposure for 3 days, stained
with acridine orange, washed, and observed by fluorescence microscopy. Acidic stained
vacuoles were still detected after treatment with Bafilomycin. All photos were taken at
20X.
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Figure 12– Assessment of DNA damage response protein expression in HCT-116 cells.
HCT-116 cells were treated with either irradiation or the indicated drugs and the
expression of p53 and p21 was assessed by western blotting at the indicated time points.
JB=JG-03-14 (500 nM) + Bafilomycin-A1 (100) nM; Tax=taxol (100nM);
Col=colchicines (100 nM); Un= untreated control; JG=JG-03-14 (500 nM); IR=irradiation
(10 Gy).
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Figure 13– Assessment of bone marrow suppression by JG-03-14 in HCT-116 cells. Bone
marrow cells were obtained from C57BL6 mice and seeded in a 24-well plates at
2 x 10^5 cells per well. Cells were incubated for 72 h with the drug treatments. Viable
cell numbers were assessed using the Alamar Blue assay. DMSO solvent was used as a
control.
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CHAPTER 4 Discussion
Colorectal cancer remains the second leading cause of cancer morbidity in
the US. There were approximately 98,200 new cases diagnosed with about
48,100 deaths in 2001 (Greenlee et al, 2001). Colon cancer is a heterogeneous
disease which evolves through two pathways: the major genetic pathway is a
consequence of chromosomal instability and accounts for 70-85% of colon cancer
cases while the non-genetic pathway, which accounts for 15% of cases, is
characterized by a loss of DNA mismatch repair system (MMR) and MSI(
microsatellite instability) (Popat et al, 2005; Jass et al, 2002; Zlobec et al, 2008).
Surgery is the primary treatment, with radiotherapy given before or after surgery to
prevent local recurrence(Mainprize et al, 1998). Although colon cancer can be
successfully treated with surgery when detected before it has metastasized out of
the colon, it has been shown that about half of the resected patients develop
recurrent disease(Sorensen et al, 2008). Colon cancer is also notoriously
unresponsive to chemotherapy. Current chemotherapeutic treatments for
colorectal cancer involve 5-fluorouracil, monoclonal antibody therapy, and
inhibitors of EGFR and VEGF (Shia, 2008;Gallegos-Arreola et al, 2008; Zrieki et
al, 2008; Schwartz RN 2008; Igbal and Lenz, 2004) . However, patient survival is
generally limited due to the development of drug resistance and metastatic
disease.
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The primary reasons that colon cancer is thought to be resistant to most
conventional chemotherapies includes mutation of p53, constitutive receptor
activation, Kras overexpression, multidrug resistance pumps, overexpression of
antiapoptotic molecules in the BcL family, silencing of DNA methylation proteins,
and constitutive activity of NFkB (Zlobec et al, 2008; Sumitomo et al, 1999;
Szakacs et al, 2006).
We have previously found that the substituted pyrrole, JG-03-14, is able to
promote cell death in both p53 wild type and p53 mutant breast tumor cells
through both autophagy and apoptosis (Arthur et a, 2007). Autophagy is the
primary mode of cell death in the MCF-7 cells while both autophagy and apoptosis
were observed in the MDA-MB-231 cells. We reasoned that if one of the reasons
for colon cancer resistance to therapy is its capacity to evade apoptosis, then a
drug that promotes autophagy might be effective.
We performed studies using the HCT-116 colon cancer cell line. One
reason for choosing this line is that isogenic lines with disruption of p53 and p21
are available for comparative studies ( although these studies will be performed in
the future). HCT-116 cells were sensitive to JG-03-14 at 250 nM and 500 nM
concentrations; at the 500 nM concentration, JG-03-14 demonstrated growth
inhibition of 75% compared to the untreated control. This was also the
concentration that was effective against MCF-7, MCF-7/caspase-3, and MDA-MB231 cells in previous studies from this laboratory (Arthur et al, 2007). The
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microtubule stabilizer, taxol, and the microtubule destabilizer, colchicine, similarly
inhibited growth of HCT-116 cells, although at concentrations of 100nM.
The majority of the population of cells treated with 500 nM JG-03-14 were
arrested in G2/M, a finding which correlates with the effects of other microtubule
destabilizers (Azeddine et al., 1998). HCT-116 cells treated with colchicine also
arrested in the G2/M phase after day 3 of treatment, a finding that was different
than the response to taxol in which the population was arrested in the G1 phase.
This finding suggest that there may be a difference in the way microtubule
destabilizers such as colchicine and JG-03-14 act on the cell cycle compared to
the microtubule stabilizer, taxol.
It is likely that the difference between the microtubule stabilizer and
destabilizer is in the way these compounds interact with the spindle assembly
checkpoint. The spindle assembly checkpoint is activated in the presence of
unattached kinetochores or the absence of tension between paired kinetochores
(Xia et al, 2004). Since centrioles organize the spindle apparatus that is required
for chromosome segregation, any defect in it or its kinetochores would activate the
spindle assembly checkpoint ( Rudner et al, 1996). It has been observed by Sudo
et al, (2004) that taxol, which binds on beta tubulin, stabilizes the microtubules
and interfere with the dynamics of the spindle apparatus formation and therefore
activate the spindle assembly checkpoint to arrest the cells at mitosis. This may
explain why we observe G1 cell cycle arrest in the HCT-116 cells treated with
taxol. On the other hand, the microtubule destabilizers, colchicines and JG-03-14,
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interfere with the formation of the spindle apparatus and perhaps may abolish the
formation of the spindle kinetochores completely. If it is in fact the case, then the
replicating cells lacking centrioles thus will also lack kinetochores or spindle
apparatus; without the spindle apparatus the spindle assembly checkpoint will not
be activated. Thus, the cells treated with JG-03-14 and colchicine which
presumably lack a spindle assembly checkpoint to promote arrest in G1 instead
undergo mitotic slippage and continue to re-replicate without division. However, it
is more likely that the formation of the spindle apparatus may occur before the
microtubule depolymerizers JG-03-14 and colchicine take a complete toll on
breaking down all microtubule structures (centrioles, spindles, kinetochores);
consequently, in the case of colchicines we observe a population of cell arrested in
G1 (24.79 %) and in G2 (44.28%). Since the mitotic block triggered by the spindle
assembly checkpoint is not permanent, cells can undergo mitotic slippage and rereplicate, a reason why we see the population of cells treated with colchicine and
JG-03-14 in the G2 cell cycle arrest after the first 24 hours (Weaver et al, 2005).
Once the depolymerizing agents continue to destroy the integrity of the
microtubules, the spindle assembly becomes dysfunctional; hence the cell will lack
a spindle assembly checkpoint to halt the cell cycle progression and will continue
to re-replicate and become hyperdiploid, as evident after 72 hours with JG-03-14
or colchicines treatment.
Normally, activation of p53 is triggered by DNA damage, spindle disruption,
hypoxia, radiation, or chemotherapeutics(Das et al, 2001;Amundson et al, 1998;
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Lowe 1999) Although JG-03-14 treated cells failed to demonstrate induction of
either p53 or p21, this finding is different from other studies using microtubule
poisons showing activation of p53 and p21. When p53 is induced, this generally
arrests the cells in the G1 phase of the cell cycle by activating the cdk2-cyclin-B
inhibitor p21/WAF1/Cip1; p53 can also activate the DNA damage repair response
if there is any DNA damage that requires repair before the cell can resume the
normal cell cycle. In cases where DNA damage is beyond repair, p53 may
activate the apoptotic pathway(Barboule et al, 1997; De Leonardo et al, 1997;
Khan et al, 1998). This checkpoint pathway was found to function in colchicine
and taxol studies showing the induction of p53 and p21 that eventually lead to
apoptosis, which is similar to our finding(Tao et al, 2005; Taylor et al,
1997;Masuda et al, 2003). Concurrent with the checkpoint activation, taxol at 100
nM induced a G1/S arrest with a population of cells evident in sub G1 even after
three days of treatment, indicating that taxol kill cells in part through the apoptotic
pathway (Wagenknecht et al., 1998; Blajeski et al., 2001). JG-03-14 failed to
arrest cells in a G1, which correlated with a lack of induction of p53 and p21 in our
studies.
Although there was no indication of a DNA damage response to JG-03-14,
we sought to determine if cell death might be occurring through checkpoint
independent apoptosis (Shi et al, 2008). However, Dapi staining showed that JG03-14 treatment did not cause DNA fragmentation that would be indicative of
apoptosis (Notterman, et al, 1998). The difference in the induction of p53 and p21
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and the large population of sub G1 cells found after colchicine treatment compared
to the relatively small population and the lack of p53 and p21 induction by JG-0314 raised the question of how microtubule depolymerizing agents that bind to the
same site on tubulin may activate different signaling cascades and different cell
death pathway.
With reference to the previous discussion on spindle assembly checkpoint,
the study by Chan et al, (2008) demonstrated that the functional spindle assembly
checkpoint and p53 are required for the postmitotic G1 checkpoint. Consequently,
in order for the spindle assembly checkpoint to be activated, the cells must be
actively replicating with a functional spindle assembly. In regards to the kinetics of
microtubule assembly, microtubules grow toward the (+) end of the beta tubulin, in
which tubulin-GTP addition is coupled directly to the hydrolysis of a longitudinally
adjacent tubulin-GTP also known as the Lateral Cap Model (Vandecandelaere et
al, 1999). The microtubules will grow with the addition of one tubulin-GTP and will
shrink at the rate of hydrolysis of one tubulin-GTP at a steady state; the affinity of
tubulin-GTP for a site at the end of the microtubule is highest when tubulin-GTP
content at the site is high The polymerization of tubulin-GTP to the (+) beta end is
found to stabilize the microtubule structure, where lack of such structure would
make the ends unstable and rapidly depolymerize whereas the (-) alpha end tends
to be stable when exposed and would resume polymerization (Desai et al, 1997).
In addition, microtubule associated proteins (MAP) are found to act with tubulin on
the alpha and beta interface to stabilize the microtubules and phosphorylation of
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MAPs can lead to increased microtubule turnover (Rodionov et al, 1990; McNally
1996). Now, recall that colchicine binds on the beta tubulin where it prevents beta
(+) tubulin-GTP from being polymerize, or added to the microtubule whereas; JG03-14 binds on the alpha and beta interface of tubulin (Jayanarayan et al, 2002).
Due to this binding, JG-03-14 may have a more profound impact on the rate at
which microtubules depolymerize because: (1) by binding to the alpha and beta
interface, it can block the polymerization of tubulin at the (+) beta end as well as
prevent the (-) alpha end from resuming polymerization and (2) it could lead to
displacement of MAPs and enhance the turnover rate of microtubules. This rapid
turnover of microtubules induced by JG-03-14 may explain why the treated cells
failed to exhibit any cell cycle arrest in the premitotic G1 phase and a lack of p53
activation because (1) the cell cycle arrest in premitotic G1 requires the activation
of the spindle assembly checkpoint; (2) since JG-03-14 may bind on a site that
would enhance rapid turnover of microtubules, there would be no spindle
formation to activate the spindle assembly checkpoint; and (3) since both the
functional spindle assembly checkpoint and p53 are required for the postmitotic
G1 checkpoint, this may explain why we did not see induction of p53 in HCT-116
tumor cells. However, further work is required to ascertain whether these
hypothesis can be validated.
We observed a hyperdiploid population after treatment with JG-03-14 and
colchicine, due to the ability of cancer cells to undergo mitotic slippage out of the
G2/M arrest and re-replicate their DNA (Gross et al., 1995).

This process
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involves DNA replication without cell division where 4N cells re-replicate to form
8N and is called endoreduplication. However, this condition, which promotes
polyploidy, where cells continue to synthesize DNA but fail to undergo cytokinesis,
is thought to exist primarily in cells lacking a functional p53; where p53 is
functional, the DNA damage response acts to arrest cells in G1 post-mitotic
slippage (Stewart et al., 1999; Elhajouji et al, 1998). Studies which indicate that
p53 is required to prevent DNA reduplication are not consistent withour findings
(Aylon et al., 2006). In fact, our previous studies showed that MDA-MB-231
mutant p53 breast tumor cells, but not p53 wild type MCF-7 cells, undergo
endoreduplication(Arthur et al, 2007). The ability of the wild type p53 HCT-116
colon cancer cells to undergo mitotic slippage indicates that tumor cells can
become polyploid independent of functional wild type p53. By inducing a rapidly
activated cell death response that is independent of functional p53 (and
presumably p21) JG-03-14 may therefore bypass the common classical pathway
of acquired resistance to antineoplastic drugs through loss of checkpoint function.
However, the role of functional p53 and p21 in JG-03-14 action remains to be fully
elucidated with studies using HCT-116 cells where p53 or p21 are silenced.
Another question that arises is the basis for the difference in the mode of
cell death between microtubule destabilizers JG-03-14 and colchicine in HCT-116
cancer cells. Studies have shown that although cancer cells can undergo mitotic
slippage and become hyperdiploid, this tetraploidy is still regulated by p53, and
that p53 can eventually arrest and abort the polyploidy cells through apoptosis.
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This was confirmed from our cell cycle analysis and the induction of p53 and p21
upon colchicine treatment (Cross et al., 1995; Vogel et al, 2004). However, this
was not evident in cells treated with JG-03-14, suggesting that there may be a
delayed apoptosis since we did see a small population of sub G1 cells.
Alternatively, the cells may die through autophagy.
Autophagy is a process that involves the formation of double membrane
acidic vesicles, the autophagosomes, which fuse with lysosoms to complete
protein degradation. In acridine orange-stained cells, the cytoplasm and nucleus
fluoresce bright green and dim red respectively, whereas the acidic compartments
fluoresces bright red during autophagy (Paglin et al., 2001). Our observations of
autophagic vacuoles stained using acridine orange in JG-03-14 treated cells
indicates the presence of autophagosomes. The untreated control is also stained
with acridine orange; however, there is only one acidic compartment per control
cell, situated near the nucleus. Similar to the treatment with JG-03-14, taxol and
colchicine also caused distributed acridine orange stained autophagic vacuoles
throughout the cytoplasm. The literature does indicate that in some cases
autophagy is an alternative mode of cell death when apoptosis is defective due to
p53 mutation or its inhibition (Kim et al., 2006; Yu et al., 2006). Since our cells are
not p53 deficient, this explanation would not apply. However, other work has
shown that autophagy may contribute to the tumor suppression function of p53, (
Jin 2005; Zeng et al., 2007). There was also a suggestion that p53 may be
involved in the induction of autophagy (Abida et al, 2008).
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The positive monodansylcadaverine stain confirms the presence of
autophagosomes; this is a more reliable stain for autophagic vacuole because of
its interaction with the autophagic membrane and not just the acidic compartment
of the autophagosome (Biederbick et al., 1995).
It appears that cell death in HCT-116 cells treated with JG-03-14 is due to
induction of autophagy, as there was only a very small population of sub G1 cells
that would suggest the occurrence of apoptosis. We also failed to detect evidence
of mitotic catastrophe, although this mode of cell death would be consistent with
cell enlargement. Although we do not know the exact mechanism of autophagic
death induced by JG-03-14, the literature suggests that it could be a consequence
of selective protein degradation, specifically catalase degradation causing an
accumulation of ROS or degradation of other essential proteins that would
eventually kill the cells (Yu et al., 2006; Onodera and Ohsumi, 2004). Future
studies using reactive oxygen species (ROS) inhibitors and measurement of
catalase could help to clarify this question.
Drugs that have been used in suppressing autophagy include 3methyladenine(3-MA), bafilomycin-A1, and chloroquine (Shacka et al, 2006; Boya
et al., 2005). Phosphatidylinositol 3-kinase (PI3K) is shown to be involved in the
autophagic pathway in tumor cells but has only been shown to be activated
through growth factor or amino acids (Blume-Jensen and Hunter, 2001; Vivanco
and Sawyer, 2002). 3-MA acts through inhibition of the PI3K pathway to inhibit
autophagy only during nutrient depletion but may not be a specific inhibitor for JG-
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03-14 induction of autophagic death, since the autophagy promoted by JG-03-14
is not due to nutrient deprivation that would otherwise be activated by PI3K-AktmTor (Reggiori and Klionsky, 2002). Attempts to use 3-MA for inhibition were
unsuccessful, as acidic stained vacuoles were still present when cells were coincubated with JG-03-14 at 500 nM. The persistent cell death observed may be
due to the failure of 3-MA to inhibit autophagy.
We also attempted to inhibit autophagy using Bafilomycin-A1, a vacuole
ATP-ase inhibitor that interferes with the pH of lysosomes. Bafilomycin-A1 is
shown to prevent the fusion of lysosomes to autophagosomes, thereby inhibiting
completion of autophagy (Yamamoto et al, 1998). Cells treated with BafilomycinA1 at 100 nM and JG-03-14 500 nM were enlarged and showed acridine orange
staining similar to the JG-03-14 treated cells, with continued cell death.
If autophagy is inhibited by Bafilomycin-A1 with JG-03-14 treatment, why do we
continue to see the acidic stains and cell death? Bafilomycin-A1 has the
demonstrated ability to induce accumulation of autophagic vacuoles concomitant
with apoptotic death at concentrations exceeding 10 nM (Boya et al., 2005). With
100 nM Bafilomycin-A1 treatment in combination with JG-03-14, Dapi staining
showed an abundance of nuclear damage that was not detected with JG-03-14
treatment alone. This could indicate that the co-incubation induced an alternate
mechanism of cytotoxicity and cell death, specifically apoptosis; however we
would need to assess nuclear fragmentation to clarify this question.
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Since Bafilomycin-A1 acts at the level of interfering with fusion and not
down regulation of the autophagosome formation, this may be a reason why
autophagosomes are detected after this treatment (Shacka et al., 2006). When
autophagosomes sequester protein for degradation, they may selectively
sequester essential proteins. When this occurs, and autophagy is inhibited by
Bafilomycin A-1, the cells can revert to another mode of death.
LC3-II is a proteolytic product of LC3-I protein that is required for the
formation of autophagosomes and is a known marker of autophagy. Before the
induction of autophagy, GFP-LC3 shows a diffuse localization of green within the
cytoplasm; once autophagy is induced, GFP-LC3 will appear as a punctuated dot
that is distributed in the cytoplasm (Zeng et al., 2007). Our GFP-LC3-II punctuate
pattern within the cytoplasm is consistent with autophagic activity after incubation
with JG-03-14 500 nM. Unfortunately, since we failed to include an untreated
control(Niemann et al., 2000), this assay is not fully confirmatory of autophagy.
In summary, our studies lead to a number of conclusions. Although the
response to JG-03-14 was found to occur at a higher concentration than colchicine
and taxol, JG-03-14 did not show bone marrow toxicity and thus may have a
higher therapeutic index compared to the other two agents. Colchicine is not used
in the clinic because it has been shown to be a substrate for the p-glycoprotein
MDR pump as well as the glutathione S-transferase found in resistant cells (RuizGomez et al, 2000). Colchicine has also been shown to suppress bone marrow
function (Liu et al, 2008; Harris et al, 2000).
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Different microtubule targeting agents can cause either a G1 or G2 arrest,
and the arrest may be p53-dependent or p53 independent. The fact that JG-03-14
induced a G2 arrest and there was no induction of p53 indicates that JG-03-14 is
acting through a p53 independent mechanism. This is significant in that cancers
that acquire resistance via evasion of the p53-dependent mechanism may be
sensitive to the alternative mechanism of cell cycle arrest which could ultimately
lead to an alternative death signal. Since adjuvant radiotherapy is often used in
preventing colon cancer recurrence, a G2/M block induced by JG-03-14 could also
stage the colon cancer cells for radio sensitization (Jorgensen et al, 2007).
The results presented above have potentially important implications for JG03-14 as a clinically effective agent due to its ability to promote autophagy in colon
cancer cells. By targeting autophagic induction of tumor regression, JG-03-14
may be able to bypass colon cancer’s high metastatic rate and resistance to
apoptosis; furthermore, JG-03-14 is not a substrate for the multidrug resistant
pump.
Drugs that target microtubules are among the most effective in treating
childhood and adult tumors. Though drugs such as combretastatin A-4 and 2ME2
bind to the same site on tubulin, they have different effects on tumor vasculature.
2ME2 has anti-angiogenic actions while combretastatin A-4 has antivascular
activities that lead to a rapid collapse in tumor vasculature (Mooberry et al, 2003,
Griggs et al, 2001). The ability of JG to bind to tubulin and its action as a
destabilizer generated interest in its potential effect on tumor vasculature.
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Angiogenesis begins with the recruitment of angioblasts and other extracellular
matrix proteins. Subsequently, maturation into endothelial cells is crucial for
vascular tubule formation (Tozer et al, 1999). Unpublished studies by our
collaborator, Dr. Edward Schwartz, showed that JG-03-14 at 100 nM was able to
inhibit endothelial cell tube formation, attachment, and migration, which indicates
that JG-03-14 may have potential as a chemotherapeutic drug for cancer.
Another reason why JG-03-14 has potential as a chemotherapeutic is that it
may not induce bone marrow toxicity. Bone marrow toxicity has been an issue
with many chemotherapeutics such as colchicine and taxol, which limits their use
in cancer treatment (Liu et al, 2008; Cardinali et al, 1961).
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